Pardeep Kumar1, Sushil Kumar Tripathi1, Chang-Po Chen2, Neil Mehta1, Bishnuhari Paudyal1, Eric Wickstrom3,4, Mathew L Thakur1,4,5. 1. 1 Department of Radiology, Thomas Jefferson University , Philadelphia, Pennsylvania. 2. 2 School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China . 3. 3 Department of Biochemistry and Molecular Biology, Thomas Jefferson University , Philadelphia, Pennsylvania. 4. 4 Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, Pennsylvania. 5. 5 Department of Radiation Oncology, Thomas Jefferson University , Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells. To determine a suitable chelating agent for labeling with (68)Ga, they have compared the labeling kinetics and stability of these peptide conjugates. METHODS: For labeling, (68)GaCl3 was eluted in 0.1 M HCl from a [(68)Ge-(68)Ga] generator. The influences of peptide concentration, pH, and temperature on the radiolabeling efficiency were studied. The stability was evaluated in saline, human serum, DTPA, transferrin, and metallic ions (FeCl3, CaCl2, and ZnCl2). Cell binding assay was performed using human breast cancer cells (T47D). Tissue biodistribution was studied in normal athymic nude mice. RESULTS: Optimal radiolabeling (>95.0%) of the DOTA-peptide conjugates required a higher (50°C-90°C) temperature and 10 minutes of incubation at pH 2-5. The NODAGA-peptide conjugate needed incubation only at 25°C for 10 minutes. Both radiocomplexes were stable in saline, serum, as well as against transchelation and transmetallation. Cell binding at 37°C for 15 minutes of incubation with (68)Ga-NODAGA-peptide was 34.0% compared to 24.5% for (68)Ga-DOTA-peptide. Tissue biodistribution at 1 hour postinjection of both (68)Ga-labeled peptide conjugates showed clearance through the kidneys. CONCLUSIONS: NODAGA-peptide showed more convenient radiolabeling features than that of DOTA-peptide.
OBJECTIVE: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide (pituitary adenylate cyclase-activating peptide [PACAP] analogue) that has a high affinity for VPAC1 receptors expressed on cancer cells. To determine a suitable chelating agent for labeling with (68)Ga, they have compared the labeling kinetics and stability of these peptide conjugates. METHODS: For labeling, (68)GaCl3 was eluted in 0.1 M HCl from a [(68)Ge-(68)Ga] generator. The influences of peptide concentration, pH, and temperature on the radiolabeling efficiency were studied. The stability was evaluated in saline, human serum, DTPA, transferrin, and metallic ions (FeCl3, CaCl2, and ZnCl2). Cell binding assay was performed using humanbreast cancer cells (T47D). Tissue biodistribution was studied in normal athymic nude mice. RESULTS: Optimal radiolabeling (>95.0%) of the DOTA-peptide conjugates required a higher (50°C-90°C) temperature and 10 minutes of incubation at pH 2-5. The NODAGA-peptide conjugate needed incubation only at 25°C for 10 minutes. Both radiocomplexes were stable in saline, serum, as well as against transchelation and transmetallation. Cell binding at 37°C for 15 minutes of incubation with (68)Ga-NODAGA-peptide was 34.0% compared to 24.5% for (68)Ga-DOTA-peptide. Tissue biodistribution at 1 hour postinjection of both (68)Ga-labeled peptide conjugates showed clearance through the kidneys. CONCLUSIONS: NODAGA-peptide showed more convenient radiolabeling features than that of DOTA-peptide.
Entities:
Keywords:
breast cancer; chelating agent; peptides; prostate cancer; radiopharmaceuticals
Authors: Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur Journal: J Nucl Med Date: 2007-12-12 Impact factor: 10.057
Authors: Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner Journal: Nucl Med Commun Date: 2007-11 Impact factor: 1.690